Noriko Mori1,
Flonn Wildes1, Kristine Glunde2, Zaver M. Bhujwalla2
1JHU
ICMIC Program, The Russell H. Morgan Department of Radiology and Radiological
Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United
States; 2JHU ICMIC Program, The Russell H. Morgan Department of
Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD,
United States
Increased levels of choline kinase (Chk)-α and phosphocholine (PC) are consistently observed in aggressive cancers. Understanding the roles of Chk and PC in cancer cells provide new insights into the malignant phenotype and can lead to the development of new treatment strategies. We previously showed that a Chk inhibitor which reduces PC had no effect on MDA-MB-231 cell proliferation, but downregulation of Chk with siRNA reduced proliferation. Here we have expanded upon these studies using SUM149 triple negative inflammatory breast cancer cells. These data confirm the importance of the enzyme, but not its activity, in breast cancer cell proliferation.